Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (I1 CR) to BAVC conditioning regimen followed by unpurged ABMT. Transplant was done after a median of 2 months from If CR (range, 1 to 13). Median first remission (I CR) duration was 1 6 months (range. 1-35) . Conditioning regimen was well tolerated, with no major extra-medullary toxicity. One patient died during aplasia from fungal sepsis. Of the 20 ATIENTS WITH ACUTE myelogenous leukemia
P (AML) in first remission (I CR) have a 15% to 25% probability of cure. Better results are reported in children, 30% to 40% of whom are probably cured.' After relapse, prognosis in both children and adults is very poor. Although it is possible to achieve a second remission (I1 CR) with intensive polychemotherapeutical schedule, in more than 50% of the cases, a probability of long-term survival (LTS) of less than 5% has been reported in the majority of studies. * New regimens of intensive polychemotherapy as postremission treatment have been used in I CR. The results, although preliminary, demonstrate the feasibility of these new strategies, with a significant increase in the proportion of LTS.' When patients in I1 C R are considered, no data concerning similar intensive post-remission schedules are available so far.
Higher doses of chemo/radiotherapy followed by autologous stem cell reinfusion represent a promising therapeutical approach in the treatment of acute leukemia patients. Autologous bone marrow transplantation (ABMT) was primarily evaluated in patients with acute leukemia in r e l a p~e .~ In this area many groups established that new remissions could be achieved in 70% to 80% of cases, but these were of short duration with less than 5% being long-term survivor^.^ These results have led to anticipation of ABMT at early stages of the disease, during CR. In I CR transplanted patients, a 40% to 50% probability of LTS has been reported. However, results from different centers are not easily comparable because of heterogeneity of population and methods (eg, induction treatment, conditioning regimens, consolidation of remission, timing of transplant, type of disease, purging procedures).6 ABMT represents an elective treatment in AML in I1 CR, since the 20% to 30% chance of LTS achieved in transplanted patients is clearly superior as compared with the results of chemotherapy alone.*
We report 21 patients affected by AML in I1 CR treated with BAVC high-dose chemotherapy regimen followed by cryopreserved autologous bone marrow reinfusion. The toxicity and the therapeutic efficacy of this approach will be analyzed.
PATIENTS AND METHODS
Between October 1984 and August 1988, 21 consecutive AML patients without HLA compatible donor and suitable for a regimen of aggressive chemotherapy entered this study. In all cases, an informed consent was obtained. The results were analyzed as of January 31, 1990. Details of patients' characteristics are shown in Table 1 : median age was 24 years (range, 1 to 47), eight were female; and according to FAB classification, the patients were allocated as M , (6) . M, (6), M, (4), M, (4), M, (1) . Median first CR duration was 16 months (range, 1 to 35). ABMT was done after a median of 2 months (range, 1 to 13) from reaching second CR. Seven patients were induced in I1 C R with high-dose cytosine arabinoside (ARA-C; 3 g/m2 twice a day x3 days) plus either AMSA or Idarubicin or L-asparaginase; 10 patients with intermediate dose of ARA-C (1 g/m*/d x 6 days) plus Mitoxantrone (6 mg/m2/d x 6 days). Four patients received ARA-C at conventional doses plus either daunorubicin (3 + 7 schedule) in one patient or AMSA and 6-thioguanine (AAT schedule) in the other three cases. After complete remission, a consolidation with the same drugs used for induction was done in 12 cases while the others underwent directly ABMT.
The techniques of marrow collection, cryopreservation, and reinfusion have been previously described.' Seventeen patients underwent marrow collection immediately before the start of pretransplant chemotherapy, and four were harvested during I CR. A median of 1.4 x 10* nucleated marrow cells per kilogram of body weight (range, 2 to 3.0) were collected from posterior iliac crests while patients were under general anesthesia.
All patients received prior bone marrow reinfusion, a four-drug original schedule (BAVC; consisting of BCNU [800 mg/m' on day -61, AMSA [150 mg/m2 on days -5, -4, and -31, VP-16 [150 mg/m2 on days -5, -4, and -31, and ARA-C [300 mg/m'continuous infusion on days -5, -4, and -31) followed after 2 days rest by bone marrow infusion.
Patients were nursed in a reverse isolation single room, with a central venous catheter placed for the administration of chemotherapy, blood products, and fluids. Bowel decontamination was done with either norfloxacine or cotrimoxazole. Broad spectrum antibiotics were given for fever during aplasia, adding amphotericin B when a persistent fever or a documented fungal infection occurred. All patients at risk for the recurrence of herpes virus infection received prophylactic intravenous acyclovir.
Bone marrow processing.
Preparative regimen. All blood products were irradiated with 20 Gy before infusion to prevent possible graft-versus-host reactions.
Supportive care,

RESULTS
Toxicity.
Conditioning regimen was well-tolerated and only various degrees of nausea and vomiting were observed during administration of chemotherapy. Four patients developed severe oral mucositis that generally resolved at the time of bone marrow engraftment. N o episodes of severe hemorrhage were observed. Sixteen patients had fever during aplasia: in 10 of 16 (62%), fever was associated with positive cultures for bacteria (nine patients) or fungus (one patient). One patient died in aplasia 1 month after bone marrow reinfusion of candida albicans sepsis. In 2 of 21 patients, clinical symptoms of pulmonary distress, including rapidly progressing dyspnea, dry cough, and tachypnea were observed a t 3 months from transplant. Pulmonary function tests revealed arterial hypoxemia, marked reduction of residual volume and total lung capacity, and decreased CO, diffusion; a pattern of diffuse interstitial infiltration was observed a t chest x-ray of the two patients. Bacterial, viral, and fungal etiologies were excluded by culture and serologic tests; bronchoalveolar lavages were not done. Low-dose steroid treatment was given, resulting in disappearance of all clinical signs and x-ray normalization in both cases. Periodic lung-function studies showed progressive improvement of restrictive pattern with return to pretransplant values after 6 and 8 months, respectively.
One patient died on day +31 without evidence of engraftment. In the remaining 20 patients, the median time required to attain an absolute neutrophil count
Engraftment.
in excess of 0.5 x 109/L was 18 days (range, 1 1 to 35) . A platelet count exceeding 50 x 109/L was observed after a median of 31 days (range, 13 to 180). Only six cases took more than 50 days to achieve 50 x 109/L platelets. No correlation was observed between the number of nucleated bone marrow cells or granulocyte-macrophage colonyforming cells reinfused and the rate of hematologic recovery.
As of January 31, 1990, 1 1 of 20 evaluable patients are in continuous complete remission (CCR) with a median follow-up of 40 months (range, 24 to 63). Eight patients relapsed in the bone marrow, and one patient had an isolated meningeal relapse. Median time to relapse was 6 months (range, 2 to 18). In all CCR patients the duration of I CR was shorter compared with both overall I1 CR and post-ABMT I1 CR duration. Among patients relapsed after ABMT, a I1 CR duration greater than the first one was observed only in the case that had an isolated central nervous system (CNS) relapse.
Projected probability of disease-free survival (DFS) of all 21 transplanted patients at 63 months is 52% (Fig l) , with a probability of relapse of 45% (Fig 2) . Of the four patients who received ABMT with marrow collected and cryopreserved in I CR, three relapsed after 4, 6, and 6 months, respectively; and one is in CCR after 50 months. Among the remaining 17 patients who underwent ABMT with marrow collected in I1 CR, 10 are still in CCR with a DFS of 59% at 63 months (Fig 1) . No relationship between probability of CCR and length of first CR, FAB classification, time of bone marrow collection, sex, age, and consolidation therapy was observed. According to second induction treatment, a trend 
DISCUSSION
In this study, 21 AML patients in I1 CR were submitted to BAVC regimen followed by autograft. Eleven patients (52%) are in CCR after a median follow-up of 40 months (range, 24 to 63). follow-up of transplanted patients. Otherwise our experience with BAVC in 55 AML patients autografted in I CR confirms the feasibility of this schedule, with less than 5% of transplant procedure-related deaths.' Apart from data by the Leukemia Intergroup, which reported more than 30% of DFS at 12 months in first relapse AML patients induced into a second remission with high dose ARA-C -+ AMSA,'' once patients relapse, few, if any, can be cured by further chemotherapy without bone marrow transplantation. Therefore, ABMT represents to date a promising alternative approach to allogeneic bone marrow transplantation. However, no conclusions can be drawn from our study and other experiences about its exact role, because of the small series of patients and the heterogeneity of populations in the retrospective studies.
There is still a variety of major issues to be solved. First, what is the best conditioning regimen in terms of feasibility and antileukemic effect? Second, can a chemotherapy schedule in relapse influence the outcome of patients? Third, does the addition of purging procedures to an autologous transplant increase relapse free survival? Prospective cooperative randomized trials are required to answer these questions. 
